Auro Laboratories Limited (530233) Fair Value & Analysis
Other · IN · Market cap ₹531M
Fair value as of: Jul 4, 2026
From 12 valuation models · updated 4 days ago
Share price −3.0% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹179.25 – ₹302.05 · fair‑value band ₹51.49 – ₹95.62 · the ₹255.00 price screens above the ₹73.55 fair value. As of Jul 4, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Auro Laboratories Limited (530233) currently trades at ₹255.00, while our model-based Fair Value estimate is ₹73.55 — implying the stock looks roughly 71.2% overvalued today. We read business quality at 44/100 (below-average quality), in the Other sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, Auro Laboratories Limited generated revenue of ₹464M at a net margin of 11.1%. Revenue grew 40.8% year over year. It earns a return on equity of 22.8%. Net debt stands at ₹619M. Fundamentals as of Jul 4, 2026
Our scenario range runs from ₹51.49 (bear case) to ₹95.62 (bull case); at ₹255.00, the current price sits above that range. The share trades about 20% below its 52-week high and 60% above its 52-week low, currently above its 200-day average. For context, the median of 10 Other peers we cover trades at -16% fair-value upside — at -71%, 530233 screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 4, 2026. TTM = trailing twelve months.
About the company
Auro Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs), intermediates, and generic formulations in India. It offers APIs for various drugs, such as antihistamine, muscle relaxant, diuretic, iron deficiency, anti-diabetic, anti-fungal, anti-ulcer, iodine supplement, anti-malaria, analgesics, antacids, and anti-inflammatory, as well as for other products, including potassium iodide, sodium iodide, and microcrystalline cellulose. The company also provides specialty chemicals comprising guanidine nitrate; dimethyl amine HCl; 2-ethoxy benzoic acid; and trimethoxy benzoic acid. In addition, it offers intermediates consisting of glibenclamde sulphonamide for use in API glibenclamide; cis-bramo benzoate and cls-tosylate that are used in API Ketoconazol; trimethoxy benzoic acid; 2-ethoxy benzoic acid for use in API sildenafil citrate; and 5-bromo phthalide that is used in API citalopram. It also exports products to Egypt, Germany, Malaysia, Singapore, …
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Auro Laboratories Limited reported revenue of ₹307M in FY2026 versus ₹509M in FY2022, a compound −11.8%/yr. Reported net income was ₹35.3M in FY2026, compounding +5.6%/yr from FY2022.
Is 530233 fairly valued? → Check now
Similar stocks
10 more Other stocks, each showing price versus our Fair Value estimate (as of Jul 4, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| There MOH | €521.90 | €269.92 | -48% |
| Sony Corporation SON1 | €17.58 | €37.56 | +114% |
| Federal Home Loan Mortgage Corporation FREJO | $16.84 | $64.93 | +286% |
| 533278 533278 | ₹438.60 | ₹720.31 | +64% |
| Nestl?? India Limited 500790 | ₹1,459 | ₹279.60 | -81% |
| 540376 540376 | ₹3,993 | ₹1,806 | -55% |
| 540777 540777 | ₹567.55 | ₹142.69 | -75% |
| Lupin Limited 500257 | ₹2,476 | ₹2,372 | -4% |
| 540719 540719 | ₹1,788 | ₹850.02 | -52% |
| 524804 524804 | ₹1,620 | ₹1,368 | -16% |
Explore undervalued stocks
Frequently asked questions
Is Auro Laboratories Limited (530233) undervalued?
What is the fair value of 530233?
What is the quality score of 530233?
What is the revenue of Auro Laboratories Limited (530233)?
What is the net profit margin of 530233?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.